Olivier Dirat

Olivier Dirat is a Senior Director in Global Regulatory Sciences CMC at Pfizer UK, currently leading the Brands CMC Team and the CMC Advisory Office. With over 22 years of experience in big pharma, Olivier has played a key role in launching and registering several significant therapies, including Dacomitinib, Talazoparib, Comirnaty, and Paxlovid. They are recognized for their expertise in CMC regulatory strategies, impurities management, and continuous manufacturing, and they actively participate in numerous regulatory and industry organizations. Olivier holds a Postdoctoral degree in Organic Chemistry from Stanford University and has contributed to 30 publications and 3 patents.